Evoke Pharma, Inc. (EVOK) 10-Year Financial Performance & Capital Metrics

EVOK • • Industrial / General

HealthcareSpecialty & Generic PharmaSpecialty PharmaceuticalsGastrointestinal Therapeutics

AboutEvoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.Show more

Revenue $10M +97.8%
EBITDA $0 +100.0%
Net Income -$5M +31.3%
EPS (Diluted) -2.81 +90.0%
Gross Margin 96.52% +0.4%
EBITDA Margin -
Operating Margin -50.78% +64.6%
Net Margin -52.22% +65.3%
ROE -240.09% +76.8%
ROIC -608.46% -12.0%
Debt/Equity 0.73
Interest Coverage -10.38 +30.2%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 96 (top 4%)
✓Trading near 52-week high

✗Weaknesses

✗Negative free cash flow
✗Shares diluted 100.0% in last year

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y85.03%

TTM67.4%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM14.98%

EPS CAGR

10Y-

5Y-

3Y-

TTM78.54%

ROCE

10Y Avg-180.96%

5Y Avg-213.34%

3Y Avg-167.93%

Latest-228.28%

Peer Comparison

Gastrointestinal Therapeutics

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
IRWDIronwood Pharmaceuticals, Inc.	735.31M	4.52	821.82	-20.63%	8.42%		14.06%
TAKTakeda Pharmaceutical Company Limited	51.59B	16.33	0.49	7.45%	0.75%	0.46%	100%	0.73
RDHLRedHill Biopharma Ltd.	6.67M	1.31	-0.19	23.17%	-97.52%
EVOKEvoke Pharma, Inc.	18.95M	11.00	-3.91	97.84%	-36.23%	-155.44%		0.73

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	23.02K	1.62M	2.51M	5.18M	10.25M
Revenue Growth %	-	-	-	-	-	-	69.29%	0.55%	1.07%	0.98%
Cost of Goods Sold+	0	0	0	0	0	86.71K	328.12K	370.39K	201.88K	356.53K
COGS % of Revenue	-	-	-	-	-	3.77%	0.2%	0.15%	0.04%	0.03%
Gross Profit+	0	0	0	0	0	-63.69K	1.29M	2.14M	4.98M	9.89M
Gross Margin %	-	-	-	-	-	-2.77%	0.8%	0.85%	0.96%	0.97%
Gross Profit Growth %	-	-	-	-	-	-	21.25%	0.66%	1.33%	0.99%
Operating Expenses+	11.82M	10.54M	11.23M	8.01M	7.15M	12.98M	9.44M	9.92M	12.41M	15.1M
OpEx % of Revenue	-	-	-	-	-	564.02%	5.84%	3.96%	2.4%	1.47%
Selling, General & Admin	3.66M	3.59M	4.09M	3.92M	3.74M	6.43M	8.85M	9.62M	12.23M	15.08M
SG&A % of Revenue	-	-	-	-	-	279.27%	5.47%	3.84%	2.36%	1.47%
Research & Development	8.15M	6.95M	7.14M	4.1M	3.42M	6.55M	590.48K	300.79K	181.91K	16.32K
R&D % of Revenue	-	-	-	-	-	284.74%	0.36%	0.12%	0.04%	0%
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-11.82M	-10.54M	-11.23M	-8.01M	-7.15M	-13.05M	-8.15M	-7.79M	-7.43M	-5.2M
Operating Margin %	-	-	-	-	-	-566.78%	-5.04%	-3.1%	-1.43%	-0.51%
Operating Income Growth %	0.1%	0.11%	-0.07%	0.29%	0.11%	-0.82%	0.38%	0.04%	0.05%	0.3%
EBITDA+	-11.52M	0	0	0	-7.13M	-13.04M	-8.04M	-7.72M	-7.29M	0
EBITDA Margin %	-	-	-	-	-	-566.54%	-4.97%	-3.08%	-1.41%	-
EBITDA Growth %	0.12%	1%	-	-	-	-0.83%	0.38%	0.04%	0.06%	1%
D&A (Non-Cash Add-back)	303.16K	10.54M	11.23M	8.01M	0	0	0	0	138.6K	5.2M
EBIT	-11.82M	-10.48M	-12.23M	-7.57M	-7.13M	-13.04M	-8.04M	-7.72M	-7.29M	-4.85M
Net Interest Income+	0	-268.03K	0	0	28.8K	-107.32K	-491.44K	-437.99K	-361.4K	-148.06K
Interest Income	0	0	0	15.21K	28.8K	5.67K	8.62K	62.01K	138.6K	353.31K
Interest Expense	0	268.03K	6.52K	15.21K	0	112.99K	500.05K	500K	500K	501.37K
Other Income/Expense	-303.16K	-204.11K	-998.83K	448.61K	28.8K	-107.32K	-386.31K	-437.99K	-361.4K	-148.06K
Pretax Income+	-12.12M	-10.75M	-12.23M	-7.57M	-7.13M	-13.15M	-8.54M	-8.22M	-7.79M	-5.35M
Pretax Margin %	-	-	-	-	-	-571.45%	-5.28%	-3.28%	-1.5%	-0.52%
Income Tax+	0	0	-6.52K	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-12.12M	-10.75M	-12.23M	-7.57M	-7.13M	-13.15M	-8.54M	-8.22M	-7.79M	-5.35M
Net Margin %	-	-	-	-	-	-571.45%	-5.28%	-3.28%	-1.5%	-0.52%
Net Income Growth %	0.09%	0.11%	-0.14%	0.38%	0.06%	-0.85%	0.35%	0.04%	0.05%	0.31%
Net Income (Continuing)	-12.12M	-10.75M	-12.23M	-7.57M	-7.13M	-13.15M	-8.54M	-8.22M	-7.79M	-5.35M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-269.13	-165.75	-118.21	-65.62	-45.84	-74.91	-40.40	-31.16	-27.97	-2.81
EPS Growth %	0.15%	0.38%	0.29%	0.44%	0.3%	-0.63%	0.46%	0.23%	0.1%	0.9%
EPS (Basic)	-269.13	-165.75	-118.21	-65.62	-45.84	-74.91	-40.40	-31.16	-27.97	-2.81
Diluted Shares Outstanding	45.04K	64.85K	103.46K	115.29K	154.83K	177.03K	223.51K	261.97K	278.56K	1.91M
Basic Shares Outstanding	45.04K	64.85K	103.46K	115.29K	154.83K	177.03K	223.51K	261.97K	278.56K	1.91M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	9.52M	9.28M	7.93M	5.65M	6.25M	9.28M	10.56M	11.72M	6.83M	17.24M
Cash & Short-Term Investments	8.69M	9.01M	7.68M	5.32M	5.66M	8.07M	9.14M	9.84M	4.74M	13.6M
Cash Only	8.69M	9.01M	7.68M	5.32M	5.66M	8.07M	9.14M	9.84M	4.74M	13.6M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	23.31K	295.19K	624.83K	673.07K	2.42M
Days Sales Outstanding	-	-	-	-	-	369.61	66.59	90.91	47.42	86.19
Inventory	0	0	0	0	0	236.48K	185.53K	289.38K	481.84K	445.08K
Days Inventory Outstanding	-	-	-	-	-	995.42	206.39	285.16	871.17	455.65
Other Current Assets	0	8K	0	0	0	30.3K	11.55K	11.55K	47.53K	43.9K
Total Non-Current Assets+	8K	11.55K	11.55K	11.55K	150.09K	153.26K	12.43K	129.07K	241.64K	281.11K
Property, Plant & Equipment	0	0	0	0	138.54K	141.71K	12.43K	129.07K	0	154.18K
Fixed Asset Turnover	-	-	-	-	-	0.16x	130.20x	19.44x	-	66.48x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	8K	11.55K	11.55K	11.55K	11.55K	11.55K	0	0	241.64K	126.93K
Total Assets+	9.53M	9.29M	7.94M	5.66M	6.4M	9.43M	10.57M	11.85M	7.07M	17.52M
Asset Turnover	-	-	-	-	-	0.00x	0.15x	0.21x	0.73x	0.59x
Asset Growth %	-0.38%	-0.02%	-0.15%	-0.29%	0.13%	0.48%	0.12%	0.12%	-0.4%	1.48%
Total Current Liabilities+	1.83M	1.41M	2.07M	1.63M	2.02M	7.54M	1.41M	1.65M	9.65M	10.38M
Accounts Payable	0	478.22K	1.05M	476.2K	1.03M	1.27M	874.03K	868.31K	1.71M	2.04M
Days Payables Outstanding	-	-	-	-	-	5.36K	972.27	855.67	3.09K	2.09K
Short-Term Debt	146.05K	0	0	0	0	104.17K	0	0	5M	5M
Deferred Revenue (Current)	-927.61K	0	0	0	0	0	0	0	0	0
Other Current Liabilities	760.78K	0	0	0	1	5M	519.32K	66K	1.32M	100K
Current Ratio	5.19x	6.58x	3.82x	3.46x	3.10x	1.23x	7.51x	7.08x	0.71x	1.66x
Quick Ratio	5.19x	6.58x	3.82x	3.46x	3.10x	1.20x	7.38x	6.91x	0.66x	1.62x
Cash Conversion Cycle	-	-	-	-	-	-4K	-699.3	-479.59	-2.18K	-1.55K
Total Non-Current Liabilities+	4.23M	4.1M	3.7M	0	0	5.11M	5.61M	6.11M	0	100.96K
Long-Term Debt	4.23M	0	0	0	0	5M	5M	5M	5M	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	100.96K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	4.1M	3.7M	0	0	112.99K	612.29K	1.11M	-5M	0
Total Liabilities	6.07M	5.51M	5.78M	1.63M	2.02M	12.65M	7.02M	7.77M	9.65M	10.48M
Total Debt+	4.38M	0	0	0	138.54K	5.25M	5.01M	5.13M	10M	5.16M
Net Debt	-4.31M	-9.01M	-7.68M	-5.32M	-5.53M	-2.82M	-4.13M	-4.71M	5.26M	-8.44M
Debt / Equity	1.26x	-	-	-	0.03x	-	1.41x	1.26x	-	0.73x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-39.34x	-1722.76x	-526.83x	-	-115.47x	-16.30x	-15.57x	-14.86x	-10.38x
Total Equity+	3.46M	3.79M	2.17M	4.03M	4.38M	-3.21M	3.56M	4.08M	-2.58M	7.04M
Equity Growth %	-0.62%	0.09%	-0.43%	0.86%	0.09%	-1.73%	2.11%	0.15%	-1.63%	3.73%
Book Value per Share	76.93	58.41	20.93	34.91	28.29	-18.16	15.91	15.59	-9.26	3.69
Total Shareholders' Equity	3.46M	3.79M	2.17M	4.03M	4.38M	-3.21M	3.56M	4.08M	-2.58M	7.04M
Common Stock	720	1.24K	1.54K	1.74K	2.44K	2.66K	272	334	28	149
Retained Earnings	-48.06M	-58.81M	-71.04M	-78.6M	-85.73M	-98.89M	-107.42M	-115.65M	-123.44M	-128.79M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-10.5M	-8.71M	-8.72M	-6.98M	-5.76M	-6.63M	-12.35M	-6.6M	-4.98M	-5.46M
Operating CF Margin %	-	-	-	-	-	-288.01%	-7.63%	-2.63%	-0.96%	-0.53%
Operating CF Growth %	0.09%	0.17%	-0%	0.2%	0.17%	-0.15%	-0.86%	0.47%	0.24%	-0.1%
Net Income	-12.12M	-10.75M	-12.23M	-7.57M	-7.13M	-13.15M	-8.54M	-8.22M	-7.79M	-5.35M
Depreciation & Amortization	0	0	0	0	0	0	0	0	0	0
Stock-Based Compensation	1.5M	1.71M	1.82M	1.54M	1.37M	1.63M	1.88M	1.46M	0	773.12K
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	43.57K	56.97K	1.01M	-433.39K	0	0	-75.13K	37.02K	1.26M	518.05K
Working Capital Changes	77.7K	277.3K	687.83K	-518.56K	-10.4K	4.9M	-5.62M	132.41K	1.55M	-1.4M
Change in Receivables	0	0	0	0	0	0	-271.88K	-329.64K	-48.24K	-1.75M
Change in Inventory	0	0	0	0	0	-236.48K	20.95K	-103.84K	-192.46K	32.84K
Change in Payables	-20.49K	-276.71K	663.16K	-440.38K	106.28K	243.36K	-527.86K	60.28K	655.13K	751.75K
Cash from Investing+	0	0	0	0	0	0	0	0	0	0
Capital Expenditures	0	0	0	0	0	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	0%	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	0	0	0
Cash from Financing+	5.03M	9.02M	7.39M	4.62M	6.11M	9.04M	13.43M	7.29M	-119.3K	14.32M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	0	0	335.23K	-1.27M	7.29M	0	7.6M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-10.5M	-8.71M	-8.72M	-6.98M	-5.76M	-6.63M	-12.35M	-6.6M	-4.98M	-5.46M
FCF Margin %	-	-	-	-	-	-288.01%	-7.63%	-2.63%	-0.96%	-0.53%
FCF Growth %	0.09%	0.17%	-0%	0.2%	0.17%	-0.15%	-0.86%	0.47%	0.24%	-0.1%
FCF per Share	-233.03	-134.28	-84.26	-60.53	-37.21	-37.45	-55.27	-25.18	-17.90	-2.87
FCF Conversion (FCF/Net Income)	0.87x	0.81x	0.71x	0.92x	0.81x	0.50x	1.45x	0.80x	0.64x	1.02x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-191.59%	-296.41%	-410.84%	-244.42%	-169.54%	-2256.53%	-5015.38%	-215.3%	-1035.44%	-240.09%
Return on Invested Capital (ROIC)	-	-	-	-	-	-	-	-	-543.44%	-608.46%
Gross Margin	-	-	-	-	-	-276.68%	79.72%	85.24%	96.1%	96.52%
Net Margin	-	-	-	-	-	-57144.53%	-527.66%	-327.83%	-150.41%	-52.22%
Debt / Equity	1.26x	-	-	-	0.03x	-	1.41x	1.26x	-	0.73x
Interest Coverage	-	-39.34x	-1722.76x	-526.83x	-	-115.47x	-16.30x	-15.57x	-14.86x	-10.38x
FCF Conversion	0.87x	0.81x	0.71x	0.92x	0.81x	0.50x	1.45x	0.80x	0.64x	1.02x
Revenue Growth	-	-	-	-	-	-	6929%	55.04%	106.51%	97.84%

Revenue by Segment

	2024
Pharmaceutical Products	10.25M
Pharmaceutical Products Growth	-

Frequently Asked Questions

Growth & Financials

Evoke Pharma, Inc. (EVOK) reported $14.4M in revenue for fiscal year 2024.

Evoke Pharma, Inc. (EVOK) grew revenue by 97.8% over the past year. This is strong growth.

Evoke Pharma, Inc. (EVOK) reported a net loss of $5.2M for fiscal year 2024.

Dividend & Returns

Evoke Pharma, Inc. (EVOK) has a return on equity (ROE) of -240.1%. Negative ROE indicates the company is unprofitable.

Evoke Pharma, Inc. (EVOK) had negative free cash flow of $3.3M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Evoke Pharma, Inc. (EVOK) 10-Year Financial Performance & Capital Metrics

EVOK • • Industrial / General

HealthcareSpecialty & Generic PharmaSpecialty PharmaceuticalsGastrointestinal Therapeutics

Revenue $10M +97.8%
EBITDA $0 +100.0%
Net Income -$5M +31.3%
EPS (Diluted) -2.81 +90.0%
Gross Margin 96.52% +0.4%
EBITDA Margin -
Operating Margin -50.78% +64.6%
Net Margin -52.22% +65.3%
ROE -240.09% +76.8%
ROIC -608.46% -12.0%
Debt/Equity 0.73
Interest Coverage -10.38 +30.2%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 96 (top 4%)
✓Trading near 52-week high

✗Weaknesses

✗Negative free cash flow
✗Shares diluted 100.0% in last year

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y85.03%

TTM67.4%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM14.98%

EPS CAGR

10Y-

5Y-

3Y-

TTM78.54%

ROCE

10Y Avg-180.96%

5Y Avg-213.34%

3Y Avg-167.93%

Latest-228.28%

Peer Comparison

Gastrointestinal Therapeutics

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
IRWDIronwood Pharmaceuticals, Inc.	735.31M	4.52	821.82	-20.63%	8.42%		14.06%
TAKTakeda Pharmaceutical Company Limited	51.59B	16.33	0.49	7.45%	0.75%	0.46%	100%	0.73
RDHLRedHill Biopharma Ltd.	6.67M	1.31	-0.19	23.17%	-97.52%
EVOKEvoke Pharma, Inc.	18.95M	11.00	-3.91	97.84%	-36.23%	-155.44%		0.73

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	23.02K	1.62M	2.51M	5.18M	10.25M
Revenue Growth %	-	-	-	-	-	-	69.29%	0.55%	1.07%	0.98%
Cost of Goods Sold+	0	0	0	0	0	86.71K	328.12K	370.39K	201.88K	356.53K
COGS % of Revenue	-	-	-	-	-	3.77%	0.2%	0.15%	0.04%	0.03%
Gross Profit+	0	0	0	0	0	-63.69K	1.29M	2.14M	4.98M	9.89M
Gross Margin %	-	-	-	-	-	-2.77%	0.8%	0.85%	0.96%	0.97%
Gross Profit Growth %	-	-	-	-	-	-	21.25%	0.66%	1.33%	0.99%
Operating Expenses+	11.82M	10.54M	11.23M	8.01M	7.15M	12.98M	9.44M	9.92M	12.41M	15.1M
OpEx % of Revenue	-	-	-	-	-	564.02%	5.84%	3.96%	2.4%	1.47%
Selling, General & Admin	3.66M	3.59M	4.09M	3.92M	3.74M	6.43M	8.85M	9.62M	12.23M	15.08M
SG&A % of Revenue	-	-	-	-	-	279.27%	5.47%	3.84%	2.36%	1.47%
Research & Development	8.15M	6.95M	7.14M	4.1M	3.42M	6.55M	590.48K	300.79K	181.91K	16.32K
R&D % of Revenue	-	-	-	-	-	284.74%	0.36%	0.12%	0.04%	0%
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-11.82M	-10.54M	-11.23M	-8.01M	-7.15M	-13.05M	-8.15M	-7.79M	-7.43M	-5.2M
Operating Margin %	-	-	-	-	-	-566.78%	-5.04%	-3.1%	-1.43%	-0.51%
Operating Income Growth %	0.1%	0.11%	-0.07%	0.29%	0.11%	-0.82%	0.38%	0.04%	0.05%	0.3%
EBITDA+	-11.52M	0	0	0	-7.13M	-13.04M	-8.04M	-7.72M	-7.29M	0
EBITDA Margin %	-	-	-	-	-	-566.54%	-4.97%	-3.08%	-1.41%	-
EBITDA Growth %	0.12%	1%	-	-	-	-0.83%	0.38%	0.04%	0.06%	1%
D&A (Non-Cash Add-back)	303.16K	10.54M	11.23M	8.01M	0	0	0	0	138.6K	5.2M
EBIT	-11.82M	-10.48M	-12.23M	-7.57M	-7.13M	-13.04M	-8.04M	-7.72M	-7.29M	-4.85M
Net Interest Income+	0	-268.03K	0	0	28.8K	-107.32K	-491.44K	-437.99K	-361.4K	-148.06K
Interest Income	0	0	0	15.21K	28.8K	5.67K	8.62K	62.01K	138.6K	353.31K
Interest Expense	0	268.03K	6.52K	15.21K	0	112.99K	500.05K	500K	500K	501.37K
Other Income/Expense	-303.16K	-204.11K	-998.83K	448.61K	28.8K	-107.32K	-386.31K	-437.99K	-361.4K	-148.06K
Pretax Income+	-12.12M	-10.75M	-12.23M	-7.57M	-7.13M	-13.15M	-8.54M	-8.22M	-7.79M	-5.35M
Pretax Margin %	-	-	-	-	-	-571.45%	-5.28%	-3.28%	-1.5%	-0.52%
Income Tax+	0	0	-6.52K	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-12.12M	-10.75M	-12.23M	-7.57M	-7.13M	-13.15M	-8.54M	-8.22M	-7.79M	-5.35M
Net Margin %	-	-	-	-	-	-571.45%	-5.28%	-3.28%	-1.5%	-0.52%
Net Income Growth %	0.09%	0.11%	-0.14%	0.38%	0.06%	-0.85%	0.35%	0.04%	0.05%	0.31%
Net Income (Continuing)	-12.12M	-10.75M	-12.23M	-7.57M	-7.13M	-13.15M	-8.54M	-8.22M	-7.79M	-5.35M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-269.13	-165.75	-118.21	-65.62	-45.84	-74.91	-40.40	-31.16	-27.97	-2.81
EPS Growth %	0.15%	0.38%	0.29%	0.44%	0.3%	-0.63%	0.46%	0.23%	0.1%	0.9%
EPS (Basic)	-269.13	-165.75	-118.21	-65.62	-45.84	-74.91	-40.40	-31.16	-27.97	-2.81
Diluted Shares Outstanding	45.04K	64.85K	103.46K	115.29K	154.83K	177.03K	223.51K	261.97K	278.56K	1.91M
Basic Shares Outstanding	45.04K	64.85K	103.46K	115.29K	154.83K	177.03K	223.51K	261.97K	278.56K	1.91M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	9.52M	9.28M	7.93M	5.65M	6.25M	9.28M	10.56M	11.72M	6.83M	17.24M
Cash & Short-Term Investments	8.69M	9.01M	7.68M	5.32M	5.66M	8.07M	9.14M	9.84M	4.74M	13.6M
Cash Only	8.69M	9.01M	7.68M	5.32M	5.66M	8.07M	9.14M	9.84M	4.74M	13.6M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	23.31K	295.19K	624.83K	673.07K	2.42M
Days Sales Outstanding	-	-	-	-	-	369.61	66.59	90.91	47.42	86.19
Inventory	0	0	0	0	0	236.48K	185.53K	289.38K	481.84K	445.08K
Days Inventory Outstanding	-	-	-	-	-	995.42	206.39	285.16	871.17	455.65
Other Current Assets	0	8K	0	0	0	30.3K	11.55K	11.55K	47.53K	43.9K
Total Non-Current Assets+	8K	11.55K	11.55K	11.55K	150.09K	153.26K	12.43K	129.07K	241.64K	281.11K
Property, Plant & Equipment	0	0	0	0	138.54K	141.71K	12.43K	129.07K	0	154.18K
Fixed Asset Turnover	-	-	-	-	-	0.16x	130.20x	19.44x	-	66.48x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	8K	11.55K	11.55K	11.55K	11.55K	11.55K	0	0	241.64K	126.93K
Total Assets+	9.53M	9.29M	7.94M	5.66M	6.4M	9.43M	10.57M	11.85M	7.07M	17.52M
Asset Turnover	-	-	-	-	-	0.00x	0.15x	0.21x	0.73x	0.59x
Asset Growth %	-0.38%	-0.02%	-0.15%	-0.29%	0.13%	0.48%	0.12%	0.12%	-0.4%	1.48%
Total Current Liabilities+	1.83M	1.41M	2.07M	1.63M	2.02M	7.54M	1.41M	1.65M	9.65M	10.38M
Accounts Payable	0	478.22K	1.05M	476.2K	1.03M	1.27M	874.03K	868.31K	1.71M	2.04M
Days Payables Outstanding	-	-	-	-	-	5.36K	972.27	855.67	3.09K	2.09K
Short-Term Debt	146.05K	0	0	0	0	104.17K	0	0	5M	5M
Deferred Revenue (Current)	-927.61K	0	0	0	0	0	0	0	0	0
Other Current Liabilities	760.78K	0	0	0	1	5M	519.32K	66K	1.32M	100K
Current Ratio	5.19x	6.58x	3.82x	3.46x	3.10x	1.23x	7.51x	7.08x	0.71x	1.66x
Quick Ratio	5.19x	6.58x	3.82x	3.46x	3.10x	1.20x	7.38x	6.91x	0.66x	1.62x
Cash Conversion Cycle	-	-	-	-	-	-4K	-699.3	-479.59	-2.18K	-1.55K
Total Non-Current Liabilities+	4.23M	4.1M	3.7M	0	0	5.11M	5.61M	6.11M	0	100.96K
Long-Term Debt	4.23M	0	0	0	0	5M	5M	5M	5M	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	100.96K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	4.1M	3.7M	0	0	112.99K	612.29K	1.11M	-5M	0
Total Liabilities	6.07M	5.51M	5.78M	1.63M	2.02M	12.65M	7.02M	7.77M	9.65M	10.48M
Total Debt+	4.38M	0	0	0	138.54K	5.25M	5.01M	5.13M	10M	5.16M
Net Debt	-4.31M	-9.01M	-7.68M	-5.32M	-5.53M	-2.82M	-4.13M	-4.71M	5.26M	-8.44M
Debt / Equity	1.26x	-	-	-	0.03x	-	1.41x	1.26x	-	0.73x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-39.34x	-1722.76x	-526.83x	-	-115.47x	-16.30x	-15.57x	-14.86x	-10.38x
Total Equity+	3.46M	3.79M	2.17M	4.03M	4.38M	-3.21M	3.56M	4.08M	-2.58M	7.04M
Equity Growth %	-0.62%	0.09%	-0.43%	0.86%	0.09%	-1.73%	2.11%	0.15%	-1.63%	3.73%
Book Value per Share	76.93	58.41	20.93	34.91	28.29	-18.16	15.91	15.59	-9.26	3.69
Total Shareholders' Equity	3.46M	3.79M	2.17M	4.03M	4.38M	-3.21M	3.56M	4.08M	-2.58M	7.04M
Common Stock	720	1.24K	1.54K	1.74K	2.44K	2.66K	272	334	28	149
Retained Earnings	-48.06M	-58.81M	-71.04M	-78.6M	-85.73M	-98.89M	-107.42M	-115.65M	-123.44M	-128.79M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-10.5M	-8.71M	-8.72M	-6.98M	-5.76M	-6.63M	-12.35M	-6.6M	-4.98M	-5.46M
Operating CF Margin %	-	-	-	-	-	-288.01%	-7.63%	-2.63%	-0.96%	-0.53%
Operating CF Growth %	0.09%	0.17%	-0%	0.2%	0.17%	-0.15%	-0.86%	0.47%	0.24%	-0.1%
Net Income	-12.12M	-10.75M	-12.23M	-7.57M	-7.13M	-13.15M	-8.54M	-8.22M	-7.79M	-5.35M
Depreciation & Amortization	0	0	0	0	0	0	0	0	0	0
Stock-Based Compensation	1.5M	1.71M	1.82M	1.54M	1.37M	1.63M	1.88M	1.46M	0	773.12K
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	43.57K	56.97K	1.01M	-433.39K	0	0	-75.13K	37.02K	1.26M	518.05K
Working Capital Changes	77.7K	277.3K	687.83K	-518.56K	-10.4K	4.9M	-5.62M	132.41K	1.55M	-1.4M
Change in Receivables	0	0	0	0	0	0	-271.88K	-329.64K	-48.24K	-1.75M
Change in Inventory	0	0	0	0	0	-236.48K	20.95K	-103.84K	-192.46K	32.84K
Change in Payables	-20.49K	-276.71K	663.16K	-440.38K	106.28K	243.36K	-527.86K	60.28K	655.13K	751.75K
Cash from Investing+	0	0	0	0	0	0	0	0	0	0
Capital Expenditures	0	0	0	0	0	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	0%	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	0	0	0
Cash from Financing+	5.03M	9.02M	7.39M	4.62M	6.11M	9.04M	13.43M	7.29M	-119.3K	14.32M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	0	0	335.23K	-1.27M	7.29M	0	7.6M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-10.5M	-8.71M	-8.72M	-6.98M	-5.76M	-6.63M	-12.35M	-6.6M	-4.98M	-5.46M
FCF Margin %	-	-	-	-	-	-288.01%	-7.63%	-2.63%	-0.96%	-0.53%
FCF Growth %	0.09%	0.17%	-0%	0.2%	0.17%	-0.15%	-0.86%	0.47%	0.24%	-0.1%
FCF per Share	-233.03	-134.28	-84.26	-60.53	-37.21	-37.45	-55.27	-25.18	-17.90	-2.87
FCF Conversion (FCF/Net Income)	0.87x	0.81x	0.71x	0.92x	0.81x	0.50x	1.45x	0.80x	0.64x	1.02x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-191.59%	-296.41%	-410.84%	-244.42%	-169.54%	-2256.53%	-5015.38%	-215.3%	-1035.44%	-240.09%
Return on Invested Capital (ROIC)	-	-	-	-	-	-	-	-	-543.44%	-608.46%
Gross Margin	-	-	-	-	-	-276.68%	79.72%	85.24%	96.1%	96.52%
Net Margin	-	-	-	-	-	-57144.53%	-527.66%	-327.83%	-150.41%	-52.22%
Debt / Equity	1.26x	-	-	-	0.03x	-	1.41x	1.26x	-	0.73x
Interest Coverage	-	-39.34x	-1722.76x	-526.83x	-	-115.47x	-16.30x	-15.57x	-14.86x	-10.38x
FCF Conversion	0.87x	0.81x	0.71x	0.92x	0.81x	0.50x	1.45x	0.80x	0.64x	1.02x
Revenue Growth	-	-	-	-	-	-	6929%	55.04%	106.51%	97.84%

Revenue by Segment

	2024
Pharmaceutical Products	10.25M
Pharmaceutical Products Growth	-

Frequently Asked Questions

Growth & Financials

Evoke Pharma, Inc. (EVOK) reported $14.4M in revenue for fiscal year 2024.

Evoke Pharma, Inc. (EVOK) grew revenue by 97.8% over the past year. This is strong growth.

Evoke Pharma, Inc. (EVOK) reported a net loss of $5.2M for fiscal year 2024.

Dividend & Returns

Evoke Pharma, Inc. (EVOK) has a return on equity (ROE) of -240.1%. Negative ROE indicates the company is unprofitable.

Evoke Pharma, Inc. (EVOK) had negative free cash flow of $3.3M in fiscal year 2024, likely due to heavy capital investments.